Telix Pharmaceuticals' shares advanced 5.2% in pre-market trading to $11.42, nearing the 52-week high of $12.48, following the company's announcement of completed patient enrollment in its Phase 3 BiPASS study. The stock had closed 2.16% lower at $10.85 the previous session, while broader U.S. equity benchmarks showed little movement.
The BiPASS trial evaluates Telix's commercial PSMA-PET imaging agents, Illuccix and Gozellix, combined with MRI against standard-of-care procedures for prostate cancer detection in the pre-biopsy setting. The company filed the enrollment update with the U.S. Securities and Exchange Commission via a Form 6-K on September 2, 2026, and noted alignment with the U.S. Food and Drug Administration on a New Drug Application pathway for the study.
Analysts at H.C. Wainwright reiterated a Buy rating and maintained a $20 price target on Telix Pharmaceuticals following the announcement. The firm's endorsement follows the company's first-half 2026 financial results, reported in August, which showed a 22% year-over-year revenue increase and a 146% rise in EBITDA.
